ARSENAL CAPITAL MANAGEMENT LP


Arsenal Capital Management LP (“Arsenal Capital Management” or “ACM”), a Delaware limited partnership formed in 2000 provides investment advisory services on a discretionary basis to several private equity funds: (i) Arsenal Capital Partners II LP, Arsenal Capital Partners QP II LP, Arsenal Capital Partners QP II-B LP and Arsenal Capital Partners Executive Fund II LP comprise “Fund II”; (ii) Arsenal Capital Partners III LP and Arsenal Capital Partners III-B LP comprise “Fund III”; and (iii) Arsenal Capital Partners IV LP, Arsenal Capital Partners IV-B LP, comprise “Fund IV”. Fund II, Fund III, Fund IV are organized to invest in portfolio companies (together with any future private equity fund to which ACM or its affiliates provide investment advisory services, each an “Arsenal Fund” and collectively the “Arsenal Funds”). In addition, ACM also provides investment advisory services to three co-investment vehicles: (i) ACP WCG Co-Invest 1 LLC (“ACP WCG Co-Invest 1”) (ii) ACP WCG Co-Invest 2 LLC (“ACP WCG Co-Invest 2”) and (iii) ACP Biospecimen Holdings, LLC (“ACP Biospecimen Holdings” and together with ACP WCG Co-Invest 1 and ACP WCG Co-Invest 2, the “Co-Invest Vehicles”, and together with the Arsenal Funds, the “Funds”). The Co-Invest Vehicles were organized to facilitate individual investments into portfolio companies of Arsenal Funds for a discrete group of co-investors. Arsenal Capital Investment II LP (“Fund II GP”), a Delaware limited partnership, serves as the general partner to Fund II. Arsenal Capital Investment III LP (“Fund III GP”), a Delaware limited partnership, serves as the general partner to Fund III. Arsenal Capital Investment IV LP (“Fund IV GP”), a Delaware limited partnership, serves as the general partner to Fund IV. ACP WCG Co- Invest 1 LLC, ACP WCG Co-Invest 2 LLC and ACP Biospecimen Holdings, LLC are each controlled by a board of managers (the “Board of Managers”). Fund II GP, Fund III GP, Fund IV GP and the Board of Managers are collectively the “General Partners.” ACM is controlled by its general partner, Arsenal Capital Group LLC, a Delaware limited liability company, which is controlled by its board of managers which consists of Jeffrey B. Kovach and Terrence M. Mullen (collectively, the “Senior Partners”). As of December 31, 2018, ACM managed approximately $3,306,199,160 on a discretionary basis. ACM serves as the management company to Fund II and Fund III. Employees of ACM comprise the Board of Managers for each of the Co-Invest Vehicles. Arsenal Capital Management IV LP (“ACM IV”), a Delaware limited partnership and an affiliate of ACM, serves as the management company of Fund IV. Arsenal Capital Management V LP (“ACM V”), a Delaware limited partnership and an affiliate of ACM, is expected to serve as the management company of a future Arsenal Fund. ACM, ACM IV, ACM V, the General Partners and other affiliates are collectively referred to as “Arsenal.” In their capacity as the management companies of the Arsenal Funds and through ACM’s appointees to the Board of Managers of the Co-Invest Vehicles, ACM and ACM IV have, and ACM V is expected to have, the authority to manage the business and affairs of the Funds. Arsenal’s investment advisory services to the Funds consist of identifying and evaluating investment opportunities, negotiating investments, managing and monitoring investments and achieving dispositions for such investments. Investments are made predominantly in non-public companies, although investments in public companies are permitted to some extent. From time to time, where such investments consist of portfolio companies, the senior professionals or other personnel of ACM or its affiliates serve on such portfolio companies’ respective boards of directors or otherwise act to influence control over management of portfolio companies held by the Funds. Arsenal makes buyout, recapitalization, and growth equity investments in the middle-market Specialty Industrial (specialty chemicals and specialty materials) and Healthcare (business services to pharmaceutical/biotech and hospital end markets; and healthcare services, with a focus on providers of clinical care) sectors. Within these sectors, Arsenal seeks to invest in businesses that have the potential for further value creation by accelerating growth and enhancing operational capabilities and competitiveness. Advisory services provided to the Funds are tailored to the investment objectives and investment restrictions, if any, as set forth in the respective Funds’ limited partnership agreements (“Partnership Agreements”), limited liability company agreements, private placement or offering memorandum, and other Fund documents (together, the “Governing Documents”). As used herein, the term “limited partners” refers to the Funds’ limited partners, shareholders and /or other investors, as applicable. Arsenal does not tailor Fund investments to the individual needs of investors in the Fund, nor may Fund investors impose restrictions on Arsenal’s ability to invest in certain securities or types of securities. The Funds’ General Partners may, however, enter into side letters or other written agreements with investors of the Funds (“Side Letters”) that have the effect of establishing rights under, or altering or supplementing the terms of, the Governing Documents of the respective Funds. Such Side Letters may be entered into with a Fund investor without the consent of or notice to any other Fund investor. Additionally, from time to time and as permitted by the relevant Governing Documents, Arsenal provides co-investment opportunities to certain investors, including limited partners, lenders, market participants, finders, other investors and Arsenal’s personnel and/or certain other persons associated with Arsenal and/or its affiliates. Such co-investments typically involve investment and disposal of interests in the applicable portfolio company at the same time and on the same terms as the Fund making the investment. However, from time to time, for strategic and other reasons, a co-investor or co-invest vehicle may purchase a portion of an investment from one or more Funds after such Funds have consummated their investment in the portfolio company (also known as a post-closing sell-down or transfer). Any such purchase from a Fund by a co-investor generally occurs shortly after the Fund’s completion of the investment to avoid any changes in valuation of the investment. Where appropriate, and in Arsenal’s sole discretion, Arsenal is authorized to charge interest on the sale to the co-investor or co-invest vehicle (or otherwise equitably adjust the purchase price under certain conditions), and to seek reimbursement to the relevant Fund for related costs. However, to the extent such amounts are not so charged or reimbursed, they will be borne by the relevant Fund. please register to get more info

Open Brochure from SEC website
Assets
Pooled Investment Vehicles $6,204,980,038
Discretionary $6,204,980,038
Non-Discretionary $
Registered Web Sites

Related news

Status Update: Aliso Viejo branch of Social Services Agency closing permanently Dec. 31

The items will be sold at one of Goodwill’s 24 local thrift stores or online at shopgoodwill.com will fund Goodwill ... is a portfolio company of Arsenal Capital Partners, a private equity ...

Shawcor Announces the Sale of its Products Business

today announced the sale of its Pipeline Performance Products business (the “Products business”) to Seal For Life Industries (“Seal For Life”), a platform of Arsenal Capital Partners, a private equity ...

Shawcor Announces the Sale of its Products Business Toronto Stock Exchange:SCL

today announced the sale of its Pipeline Performance Products business (the 'Products business') to Seal For Life Industries ('Seal For Life'), a platform of Arsenal Capital Partners, a private ...

Shawcor Announces the Sale of its Products Business

today announced the sale of its Pipeline Performance Products business (the “Products business”) to Seal For Life Industries (“Seal For Life”), a platform of Arsenal Capital Partners ...

Arsenal And Seal For Life Announce Acquisition Of Canusa

About Arsenal Capital Partners Arsenal is a leading private ... Since its inception in 2000, Arsenal has raised institutional equity investment funds of $5.3 billion, has completed more than ...

Arsenal And Seal For Life Announce Acquisition Of Canusa

About Arsenal Capital Partners Arsenal is a leading private ... Since its inception in 2000, Arsenal has raised institutional equity investment funds of $5.3 billion, has completed more than ...

Arsenal And Seal For Life Announce Acquisition Of Canusa

About Arsenal Capital Partners Arsenal is a leading private equity firm that specializes in investments in middle-market specialty industrials and healthcare companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds ...

Shawcor Announces the Sale of its Products Business

today announced the sale of its Pipeline Performance Products business (the “Products business”) to Seal For Life Industries (“Seal For Life”), a platform of Arsenal Capital Partners, a private equity investment firm based out of New York.

Arsenal And Seal For Life Announce Acquisition Of Canusa

Mutual Funds Stocks ETFs Bonds Best Investments Portfolio Markets Investing Learn Start Investing Investing Classroom Investing Glossary Help Center Plan Tax Planning Personal Finance ...

Arsenal And Seal For Life Announce Acquisition Of Canusa

About Arsenal Capital Partners Arsenal is a leading private ... Since its inception in 2000, Arsenal has raised institutional equity investment funds of $5.3 billion, has completed more than ...
Loading...
No recent news were found.